Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | TK1 | P04183 | 1/20 | 0.44 |
| ▸ | AGXT | P21549 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2433172 | 1.00 | TSHR (0.54) | TSHRALOX5IDO1TK1AGXT | |
| SCHEMBL292314 | 1.00 | TSHR (0.54) | TSHRALOX5IDO1TK1AGXT | |
| SCHEMBL1524101 | 0.89 | TSHR (0.67) | TSHRALOX5IDO1TK1AGXT | |
| SCHEMBL1524098 | 0.89 | TSHR (0.67) | TSHRALOX5IDO1TK1AGXT | |
| SCHEMBL1524411 | 0.89 | TSHR (0.67) | TSHRALOX5IDO1TK1AGXT | |
| Ammonia Solution, Strong SCHEMBL7095980 | 0.87 | TSHR (0.64) | TSHRALOX5IDO1TK1AGXT | |
| SCHEMBL641214 | 0.82 | TSHR (0.56) | TSHRALOX5IDO1TK1AGXT | |
| SCHEMBL8125435 | 0.82 | TSHR (0.56) | TSHRALOX5IDO1TK1AGXT | |
| SCHEMBL15543284 | 0.82 | TSHR (0.56) | TSHRALOX5IDO1TK1AGXT | |
| SCHEMBL641213 | 0.82 | TSHR (0.56) | TSHRALOX5IDO1TK1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689639-B | Spirolactams as ROCK inhibitors | 百时美施贵宝公司 | 2022-02-18 | — | — | CN | disclosed |
| EP-3481817-B1 | SPIROLACTAMS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | disclosed |
| US-10696674-B2 | Spirolactams as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190322664-A1 | SPIROLACTAMS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2019-10-24 | — | — | US | disclosed |
| WO-2016181312-A1 | POLYCYCLIC EPOXIDES AND COMPOSITIONS THEREOF WITH ANTI-CANCER ACTIVITIES | VERSITECH LIMITED (CN) | 2016-11-17 | — | — | WO | disclosed |
| EP-2280989-B1 | CYCLOSPORIN ANALOGS AND THEIR USE IN THE TREATMENT OF HCV INFECTIONS | SCYNEXIS INC (US) | 2016-02-10 | — | — | EP | disclosed |
| US-9090671-B2 | Macrocyclic peptides | SCYNEXIS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-8158790-B2 | Cyclic amine compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-04-17 | — | — | US | disclosed |
| EP-2036896-B1 | CYCLIC AMINE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2012-03-14 | — | — | EP | disclosed |
| CN-102083852-A | Cyclosporin analogs and their use in the treatment of HCV infections | SCYNEXIS INC | 2011-06-01 | — | — | CN | disclosed |
| EP-2280989-A2 | CYCLOSPORIN ANALOGS AND THEIR USE IN THE TREATMENT OF HCV INFECTIONS | Scynexis, Inc. (US) | 2011-02-09 | — | — | EP | disclosed |
| WO-2010002428-A2 | NOVEL MACROCYCLIC PEPTIDES | SCYNEXIS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| US-20090312300-A1 | NOVEL MACROCYCLIC PEPTIDES | CYPRALIS LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-20090286807-A1 | CYCLIC AMINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2036896-A1 | CYCLIC AMINE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2009-03-18 | — | — | EP | disclosed |
| EP-1020434-A1 | 3-AMIDINOANILINE DERIVATIVES, ACTIVATED BLOOD COAGULATION FACTOR X INHIBITORS, AND INTERMEDIATES FOR PRODUCING BOTH | Kissei Pharmaceutical Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696674-B2 | Spirolactams as inhibitors of ROCK | MYLK, ROCK1, MYLK2 | TSHR 1723/4885ALOX5 923/4885IDO1 1622/4885 |
| US-20090312300-A1 | NOVEL MACROCYCLIC PEPTIDES | CHP1, SARS1, HAVCR2 | TSHR 4284/4885ALOX5 4354/4885IDO1 1840/4885 |
| US-20090286807-A1 | CYCLIC AMINE COMPOUND | HRH3, HRH4, H1-0 | TSHR 435/4885ALOX5 754/4885IDO1 333/4885 |
| US-20190322664-A1 | SPIROLACTAMS AS INHIBITORS OF ROCK | MYLK, ROCK1, MYLK2 | TSHR 1723/4885ALOX5 923/4885IDO1 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.